Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 2,552 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,552 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76. Following the sale, the chief executive officer now owns 230,319 shares in the company, valued at $21,046,550.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total value of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total value of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $964,178.17.

Natera Stock Performance

Shares of Natera stock traded up $2.43 during trading hours on Tuesday, hitting $91.04. 1,178,233 shares of the company were exchanged, compared to its average volume of 1,470,075. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The business has a 50-day moving average of $86.40 and a 200-day moving average of $66.49. The stock has a market capitalization of $10.99 billion, a price-to-earnings ratio of -24.02 and a beta of 1.37.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. As a group, analysts expect that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and upped their price target for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a report on Friday, April 5th. BTIG Research upped their price target on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a report on Friday, December 29th. Stephens reaffirmed an “overweight” rating and issued a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. Finally, StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $86.40.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Arcadia Investment Management Corp MI raised its position in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after acquiring an additional 174 shares in the last quarter. Fifth Third Bancorp raised its position in Natera by 3.0% in the fourth quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after acquiring an additional 179 shares in the last quarter. Treasurer of the State of North Carolina raised its position in Natera by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after acquiring an additional 230 shares in the last quarter. Xponance Inc. raised its position in Natera by 1.8% in the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after acquiring an additional 261 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group raised its position in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.